دورية أكاديمية
Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
| العنوان: | Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride |
|---|---|
| المؤلفون: | Kiguradze, Tina, Temps, William H., Yarnold, Paul R., Cashy, John, Brannigan, Robert E., Nardone, Beatrice, Micali, Giuseppe, West, Dennis Paul, Belknap, Steven M. |
| المساهمون: | National Institutes of Health grants, National Institutes of Health’s National Center for Advancing Translational Sciences, Grant Numbers, Post-Finasteride Syndrome Foundation |
| المصدر: | PeerJ ; volume 5, page e3020 ; ISSN 2167-8359 |
| بيانات النشر: | PeerJ |
| سنة النشر: | 2017 |
| المجموعة: | PeerJ (E-Journal - via CrossRef) |
| الوصف: | Importance Case reports describe persistent erectile dysfunction (PED) associated with exposure to 5α-reductase inhibitors (5α-RIs). Clinical trial reports and the manufacturers’ full prescribing information (FPI) for finasteride and dutasteride state that risk of sexual adverse effects is not increased by longer duration of 5α-RI exposure and that sexual adverse effects of 5α-RIs resolve in men who discontinue exposure. Objective Our chief objective was to assess whether longer duration of 5α-RI exposure increases risk of PED, independent of age and other known risk factors. Men with shorter 5α-RI exposure served as a comparison control group for those with longer exposure. Design We used a single-group study design and classification tree analysis (CTA) to model PED (lasting ≥90 days after stopping 5α-RI). Covariates included subject attributes, diseases, and drug exposures associated with sexual dysfunction. Setting Our data source was the electronic medical record data repository for Northwestern Medicine. Subjects The analysis cohorts comprised all men exposed to finasteride or dutasteride or combination products containing one of these drugs, and the subgroup of men 16–42 years old and exposed to finasteride ≤1.25 mg/day. Main outcome and measures Our main outcome measure was diagnosis of PED beginning after first 5α-RI exposure, continuing for at least 90 days after stopping 5α-RI, and with contemporaneous treatment with a phosphodiesterase-5 inhibitor (PDE 5 I). Other outcome measures were erectile dysfunction (ED) and low libido. PED was determined by manual review of medical narratives for all subjects with ED. Risk of an adverse effect was expressed as number needed to harm (NNH). Results Among men with 5α-RI exposure, 167 of 11,909 (1.4%) developed PED (persistence median 1,348 days after stopping 5α-RI, interquartile range (IQR) 631.5–2320.5 days); the multivariable model predicting PED had four variables: prostate disease, duration of 5α-RI exposure, age, and nonsteroidal anti-inflammatory drug ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.7717/peerj.3020 |
| الإتاحة: | https://doi.org/10.7717/peerj.3020Test https://peerj.com/articles/3020.pdfTest https://peerj.com/articles/3020.xmlTest https://peerj.com/articles/3020.htmlTest |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.66C8AF84 |
| قاعدة البيانات: | BASE |
| DOI: | 10.7717/peerj.3020 |
|---|